Roivant Sciences launches new Alyvant subsidiary
Alyvant will be focused on connecting de-identified patient data with physician data to connect patient populations with suitable medications.
Alyvant will be focused on connecting de-identified patient data with physician data to connect patient populations with suitable medications.
Bad news has piled up at Axovant, including the poor showing of its Parkinsons/Lewy body drug, and now the CEO David Hung is out after a mere 10 months on the job.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Axovant founder and CEO Vivek Ramaswamy has stepped back from the top job, passing the reins to David Hung as the company nears a Phase 3 data readout for its lead Alzheimer's drug candidate.
Alzheimer's underdog Accera revealed Tuesday that its 413-patient trial of AC-1204 failed to reach its stated endpoints.
Roivant's search for overlooked and underpriced compounds continues, as it builds out more subsidiaries and completes enrollment on its first Phase 3 trial.